The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer
DOI:
https://doi.org/10.2340/1651-226X.2025.42994Keywords:
Carcinoma, ovarian epithelial, recurrence, platinum-free interval, secondary cytoreductive surgeryAbstract
Background: The prognosis in advanced ovarian cancer is generally poor since the majority experience recurrence. Nevertheless, there is a chance of cure and very long-term survival may be achieved. However, traditional survival metrics do not account for the dynamic changes in prognosis over time. Our objectives were to examine conditional, very long-term and recurrence-free survival, in addition risk-factors for recurrence.
Methods: In this observational study, all patients diagnosed with advanced ovarian cancer between 2009 and 2018 in the Stockholm/Gotland region, Sweden, were identified in the Swedish Quality Registry of Gynecologic Cancer. Conditional and recurrence-free survival were estimated with the Kaplan Meier method. The association between predefined clinical factors and hazard of death was analysed with Cox regression yielding hazard ratio (HR) with 95% confidence interval (CI).
Results: A total of 888 patients were analysed of which 87.0% (n = 740) experienced a recurrence and 8.5 % (n = 76) were alive > 10 years. The 5-year conditional survival increased from 33.0% (95% CI: 30–36) in patients who had survived 1 year to 57.0% (95% CI: 50–63) in patients who had already survived 5 years. The median recurrence-free survival was 18 months (95% CI: 16–19). Risk factors associated with recurrence included any residual tumour (> 10 mm; HR: 2.15; 95% CI: 1.65 to 2.80) and evidence of disease at end of first line treatment (HR: 2.40; 95% CI: 1.97 to 2.93; p < 0.001).
Interpretation: Conditional survival improves significantly with time survived following an advanced ovarian cancer diagnosis. Most patients experience relapse within 1 year after completing first-line treatment, nevertheless long-term survival is possible.
Downloads
References
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705.
https://doi.org/10.1093/annonc/mdz062 DOI: https://doi.org/10.1093/annonc/mdz062
Nationella Vårdprogramsgruppen för äggstockscancer. Nationellt vårdprogram för äggstockscancer, epitelial. Version 4.2, 2023; Regionala Cancercentrum. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/.
SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 [updated: 2024 Nov 5; cited 2025 Jan 21]. Available from: https://seer.cancer.gov/statistics-network/explorer/. Data source(s): SEER Incidence Data, November 2023 Submission (1975–2021), SEER 22 registries (excluding Illinois and Massachusetts). Expected Survival Life Tables by Socio-Economic Standards.
Åkeson M, Jakobsen A-M, Zetterqvist B-M, Holmberg E, Brännström M, Horvath G. A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer. 2009;19(1):116–23.
https://doi.org/10.1111/IGC.0b013e3181991b13 DOI: https://doi.org/10.1111/IGC.0b013e3181991b13
Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016;141(2):260–3.
https://doi.org/10.1016/j.ygyno.2016.03.010 DOI: https://doi.org/10.1016/j.ygyno.2016.03.010
Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126(3):491–7.
https://doi.org/10.1097/AOG.0000000000000981 DOI: https://doi.org/10.1097/AOG.0000000000000981
Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018;148(1):204–12.
https://doi.org/10.1016/j.ygyno.2017.10.032 DOI: https://doi.org/10.1016/j.ygyno.2017.10.032
Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, et al. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018;148(2):275–80. DOI: https://doi.org/10.1016/j.ygyno.2017.11.018
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.
https://doi.org/10.1002/cncr.24149 DOI: https://doi.org/10.1002/cncr.24149
Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer. 2022;128(16):3080–9.
https://doi.org/10.1002/cncr.34350 DOI: https://doi.org/10.1002/cncr.34350
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28.
https://doi.org/10.1056/NEJMoa1911361 DOI: https://doi.org/10.1056/NEJMoa1911361
Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33(8):937–43.
https://doi.org/10.1200/JCO.2014.56.3106 DOI: https://doi.org/10.1200/JCO.2014.56.3106
Falconer H, Joneborg U, Krawiec K, Palsdottir K, Bottai M, Salehi S. Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population. Gynecol Oncol. 2020;159(1):58–65.
https://doi.org/10.1016/j.ygyno.2020.07.009 DOI: https://doi.org/10.1016/j.ygyno.2020.07.009
Ehmann S, Shay K, Zhou Q, Iasonos A, Sonoda Y, Gardner GJ, et al. Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: a Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2023;169:118–24.
https://doi.org/10.1016/j.ygyno.2022.12.009 DOI: https://doi.org/10.1016/j.ygyno.2022.12.009
Shalowitz DI, Epstein AJ, Ko EM, Giuntoli RL, 2nd. Non-surgical management of ovarian cancer: prevalence and implications. Gynecol Oncol. 2016;142(1):30–7.
https://doi.org/10.1016/j.ygyno.2016.04.026 DOI: https://doi.org/10.1016/j.ygyno.2016.04.026
Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, et al. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol. 2018;151(1):24–31.
https://doi.org/10.1016/j.ygyno.2018.08.014 DOI: https://doi.org/10.1016/j.ygyno.2018.08.014
Norppa N, Staff S, Helminen M, Auranen A, Saarelainen S. Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: results from a tertiary referral center. Gynecol Oncol. 2022;165(3):478–85.
https://doi.org/10.1016/j.ygyno.2022.03.023 DOI: https://doi.org/10.1016/j.ygyno.2022.03.023
Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85.
https://doi.org/10.1097/01.AOG.0000192407.04428.bb DOI: https://doi.org/10.1097/01.AOG.0000192407.04428.bb
Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.
https://doi.org/10.1016/S0140-6736(10)61268-8 DOI: https://doi.org/10.1016/S0140-6736(10)61268-8
Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1–7.
https://doi.org/10.1016/j.ajog.2007.10.495 DOI: https://doi.org/10.1016/j.ajog.2007.10.495
Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309–10.
https://doi.org/10.1016/S0140-6736(02)08272-7 DOI: https://doi.org/10.1016/S0140-6736(02)08272-7
Szamreta EA, Monberg MJ, Desai KD, Li Y, Othus M. Prognosis and conditional survival among women with newly diagnosed ovarian cancer. Gynecol Oncol. 2024;180:170–7.
https://doi.org/10.1016/j.ygyno.2023.11.018 DOI: https://doi.org/10.1016/j.ygyno.2023.11.018
Shin DW, Bae J, Ha J, Jung KW. Conditional relative survival of ovarian cancer: a Korean National Cancer Registry Study. Front Oncol. 2021;11:639839.
https://doi.org/10.3389/fonc.2021.639839 DOI: https://doi.org/10.3389/fonc.2021.639839
Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H, et al. Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol. 2010;28(15):2520–8.
https://doi.org/10.1200/JCO.2009.25.9697 DOI: https://doi.org/10.1200/JCO.2009.25.9697
Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129(3):439–47.
https://doi.org/10.1097/AOG.0000000000001867 DOI: https://doi.org/10.1097/AOG.0000000000001867
Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.
https://doi.org/10.1093/annonc/mds203 DOI: https://doi.org/10.1093/annonc/mds203
Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2014;89(2):207–16.
https://doi.org/10.1016/j.critrevonc.2013.08.017 DOI: https://doi.org/10.1016/j.critrevonc.2013.08.017
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123–31.
https://doi.org/10.1056/NEJMoa2103294 DOI: https://doi.org/10.1056/NEJMoa2103294
Jiang R, Feng Y, Chen Y, Cheng X, Shi T, Gao W, et al. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat Med. 2024;30(8):2181–8.
https://doi.org/10.1038/s41591-024-02981-0 DOI: https://doi.org/10.1038/s41591-024-02981-0
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–39.
https://doi.org/10.1056/NEJMoa1902626 DOI: https://doi.org/10.1056/NEJMoa1902626
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Nina Groes Kofoed, Henrik Falconer, Matteo Bottai, Sahar Salehi
This work is licensed under a Creative Commons Attribution 4.0 International License.
